Literature DB >> 30042128

Mechanisms of inside-out signaling of the high-affinity IgG receptor FcγRI.

Arianne M Brandsma1, Samantha L Schwartz2, Michael J Wester2, Christopher C Valley2, Gittan L A Blezer1, Gestur Vidarsson3, Keith A Lidke4, Toine Ten Broeke1, Diane S Lidke2, Jeanette H W Leusen5.   

Abstract

Fc receptors (FcRs) are an important bridge between the innate and adaptive immune system. Fc gamma receptor I (FcγRI; CD64), the high-affinity receptor for immunoglobulin G (IgG), plays roles in inflammation, autoimmune responses, and immunotherapy. Stimulation of myeloid cells with cytokines, such as tumor necrosis factor-α ( TNFα) and interferon-γ ( IFNγ), increases the binding of FcγRI to immune complexes (ICs), such as antibody-opsonized pathogens or tumor cells, through a process known as "inside-out" signaling. Using super-resolution imaging, we found that stimulation of cells with IL-3 also enhanced the clustering of FcγRI both before and after exposure to ICs. This increased clustering was dependent on an intact actin cytoskeleton. We found that chemical inhibition of the activity of the phosphatase PP1 reduced FcγRI inside-out signaling, although the phosphorylation of FcγRI itself was unaffected. Furthermore, the antibody-dependent cytotoxic activity of human neutrophils toward CD20-expressing tumor cells was increased after stimulation with TNFα and IFNγ. These results suggest that nanoscale reorganization of FcγRI, stimulated by cytokine-induced, inside-out signaling, enhances FcγRI cellular effector functions.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30042128     DOI: 10.1126/scisignal.aaq0891

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  9 in total

1.  iNK-CD64/16A cells: a promising approach for ADCC?

Authors:  Bruce Walcheck; Jianming Wu
Journal:  Expert Opin Biol Ther       Date:  2019-09-19       Impact factor: 4.388

Review 2.  Physical Constraints and Forces Involved in Phagocytosis.

Authors:  Valentin Jaumouillé; Clare M Waterman
Journal:  Front Immunol       Date:  2020-06-12       Impact factor: 7.561

Review 3.  FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy.

Authors:  Xin Chen; Xiaomin Song; Kang Li; Tong Zhang
Journal:  Front Immunol       Date:  2019-02-26       Impact factor: 7.561

4.  FcαRI Dynamics Are Regulated by GSK-3 and PKCζ During Cytokine Mediated Inside-Out Signaling.

Authors:  Toine Ten Broeke; Henk Honing; Arianne M Brandsma; Shamir Jacobino; Jantine E Bakema; Deon Kanters; Jan A M van der Linden; Madelon Bracke; Leo Koenderman; Jeanette H W Leusen
Journal:  Front Immunol       Date:  2019-01-31       Impact factor: 7.561

Review 5.  Inside-Out Control of Fc-Receptors.

Authors:  Leo Koenderman
Journal:  Front Immunol       Date:  2019-03-21       Impact factor: 7.561

Review 6.  The Human FcγRII (CD32) Family of Leukocyte FcR in Health and Disease.

Authors:  Jessica C Anania; Alicia M Chenoweth; Bruce D Wines; P Mark Hogarth
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

7.  Criticality of plasma membrane lipids reflects activation state of macrophage cells.

Authors:  Eugenia Cammarota; Chiara Soriani; Raphaelle Taub; Fiona Morgan; Jiro Sakai; Sarah L Veatch; Clare E Bryant; Pietro Cicuta
Journal:  J R Soc Interface       Date:  2020-02-05       Impact factor: 4.118

8.  Engineered IgG1-Fc Molecules Define Valency Control of Cell Surface Fcγ Receptor Inhibition and Activation in Endosomes.

Authors:  Elizabeth M Bailey; Amit Choudhury; Harika Vuppula; Daniel F Ortiz; John Schaeck; Anthony M Manning; Carlos J Bosques; Adam D Hoppe
Journal:  Front Immunol       Date:  2021-02-15       Impact factor: 7.561

Review 9.  Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells.

Authors:  Kate J Dixon; Jianming Wu; Bruce Walcheck
Journal:  Cancers (Basel)       Date:  2021-01-16       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.